UNSPSC 51381514: Tolmetin glycine amide

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3RS348SV6U, chemically known as glycine, n-(2-(1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl)acetyl)-, but more generally known as tolmetin glycine amide, which bears US NIH Compound Identifier 135911. European Medicines Agency schedules tolmetin glycine amide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11162MIG.

Most nations, for tariff purposes, schedule tolmetin glycine amide under HS 29339990. SMILES: CC1CCC(CC1)C(=O)C2CCC(N2C)CC(=O)NCC(=O)O.

UNSPSC 51381514 Tolmetin glycine amide (Commodity) shows minimal alignment between its nominal scope and recent state and local procurement activity. The three opportunities posted in the source relate to naloxone and drug deactivation systems, a direct-to-manufacturer pharmacy prescription program, and generic multi-source pharmaceuticals and over-the-counter products — none of which are tolmetin glycine amide, a specific nonsteroidal anti-inflammatory drug formulation. The code appears to be mislabeled or misapplied to these opportunities, suggesting that tolmetin glycine amide itself does not see active solicitation in the state and local market as indexed by recent opportunities.

The issuing bodies in the recent opportunities span county health systems (Seminole County, Florida), state human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administering on behalf of participating state and local government facilities including Oregon). The representative solicitations include a competitive IFB for naloxone and drug deactivation systems (Seminole County, response deadline July 26, 2023), a Request for Information on direct-to-manufacturer pharmacy initiatives (Texas HHS, posted April 3, 2026), and an RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (MMCAP, response deadline March 26, 2026). Geographic activity reflected in the source spans Florida, Texas, Minnesota, and Oregon. The code itself shows no recent activity specific to tolmetin glycine amide procurement.